UK Markets close in 3 hrs 25 mins
  • FTSE 100

    7,149.05
    -20.23 (-0.28%)
     
  • FTSE 250

    18,555.19
    -111.59 (-0.60%)
     
  • AIM

    873.13
    -3.09 (-0.35%)
     
  • GBP/EUR

    1.1536
    -0.0075 (-0.64%)
     
  • GBP/USD

    1.2038
    -0.0137 (-1.1232%)
     
  • BTC-GBP

    15,946.57
    +12.47 (+0.08%)
     
  • CMC Crypto 200

    413.00
    -18.46 (-4.28%)
     
  • S&P 500

    3,785.38
    -33.45 (-0.88%)
     
  • DOW

    30,775.43
    -253.88 (-0.82%)
     
  • CRUDE OIL

    108.71
    +2.95 (+2.79%)
     
  • GOLD FUTURES

    1,787.30
    -20.00 (-1.11%)
     
  • NIKKEI 225

    25,935.62
    -457.42 (-1.73%)
     
  • HANG SENG

    21,859.79
    -137.10 (-0.62%)
     
  • DAX

    12,753.20
    -30.57 (-0.24%)
     
  • CAC 40

    5,917.40
    -5.46 (-0.09%)
     

Sanofi's Dupixent gets U.S. approval to treat eczema in young children

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

(Reuters) -The U.S. Food and Drug Administration approved the use of Sanofi and Regeneron Pharmaceuticals Inc's anti-inflammation drug Dupixent to treat eczema in young children, the two companies said on Tuesday.

Dupixent is now the first approved treatment for moderate-to-severe eczema in young children, Sanofi and Regeneron said.

Sanofi records global net product sales of Dupixent, while Regeneron gets a share of profit or loss from the drug.

The approval for the drug in children aged 6 months to 5 years was based on data from a late-stage study in which Dupixent improved skin clearance and reduced severity of eczema when used with a corticosteroids cream.

The drug works by blocking the inflammation-causing IL-4 and IL-13 proteins involved in the body's immune response that the companies believe to be underlying reasons for a number of inflammatory conditions.

Dupixent, with 2021 sales of 5.25 billion euros, accounted for 13.9% of Sanofi's revenue, making it the Paris-listed company's best-selling product.

Dupixent is already approved for treating a range of diseases in adult populations in the United States, including eczema or atopic dermatitis, severe asthma and an allergic inflammation of the esophagus.

Atopic dermatitis, or eczema, is a chronic skin condition that causes inflammation and irritation of skin. It affects about 30% of the U.S. population, mostly children and adolescents, according to the National Institute of Allergy and Infectious Diseases. https://www.niaid.nih.gov/diseases-conditions/eczema-atopic-dermatitis

(Reporting by Bhanvi Satija and Leroy Leo in Bengaluru; Editing by Sriraj Kalluvila)

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting